Clinical Trials for Ovarian Cancer

A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with newly diagnosed FIGO III–IV high-grade epithelial ovarian/fallopian tube/primary peritoneal carcinoma whose tumors express HER2 (IHC 3+/2+/1+) and who completed frontline platinum plus bevacizumab are randomized to maintenance trastuzumab deruxtecan (HER2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor) plus bevacizumab versus bevacizumab alone. Excludes patients with BRCA mutations or on PARP maintenance and those with significant bleeding risk or prior/current ILD/pneumonitis.

ClinicalTrials.gov ID: NCT06819007

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 As a Single Agent and in Combination with Pembrolizumab (MK-3475-D20) in Subjects with Advanced Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced solid tumors or T-cell lymphoma receive investigational BI-1808, a TNFR2-blocking antibody designed to reduce immunosuppressive regulatory T cells, either alone or with the anti-PD-1 antibody pembrolizumab. Expansion cohorts include ovarian cancer, T-cell lymphoma, melanoma, and selected solid tumors.

ClinicalTrials.gov ID: NCT04752826

Phase II Study of Nab-sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent, histologically confirmed low-grade serous ovarian cancer (ECOG 0–1; measurable disease; prior MEK inhibitor allowed; ≤1 prior cytotoxic regimen; no prior mTOR/PI3K/AKT inhibitors) receive nab-sirolimus (albumin-bound mTOR inhibitor targeting PI3K/AKT/mTOR) IV plus fulvestrant (SERD) IM until progression or toxicity. Single-arm study with required pre-dose biopsy; key exclusions include significant cardiopulmonary disease, active uncontrolled infections, CNS disease needing recent steroids/RT, and strong CYP3A4 interactions.

ClinicalTrials.gov ID: NCT06494150

A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Maintenance combination of mirvetuximab soravtansine (FRα-targeted antibody–drug conjugate delivering DM4) plus olaparib (PARP inhibitor) for adult women with platinum-sensitive recurrent high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer who have CR/PR/SD after platinum and medium/high FRα expression (BRCA-mutated patients must have had prior PARP). Treatment continues until progression or toxicity; key exclusions include prior FRα-targeted therapy, CNS mets, significant ocular disease, and use of strong/moderate CYP3A modifiers.

ClinicalTrials.gov ID: NCT05887609

Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant high-grade serous ovarian cancer (progression within 6 months of last platinum; ECOG 0–1; any prior lines) receive oral atovaquone monotherapy. Atovaquone, an antiprotozoal repurposed here for its STAT3 pathway inhibition, is assessed for progression-free survival with correlative biopsies/ascites and imaging to evaluate on-target effects and immune microenvironment changes.

ClinicalTrials.gov ID: NCT05998135

An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm extension providing continued niraparib to adults who completed a prior GSK/TESARO niraparib study and are still benefiting, with controlled toxicities and ongoing dosing from the parent protocol. Niraparib is an oral PARP-1/2 inhibitor exploiting synthetic lethality (e.g., HRD/BRCA-mutated tumors); treatment continues until progression/toxicity with focus on long-term safety monitoring.

ClinicalTrials.gov ID: NCT04641247

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors including HNSCC, pancreatic adenocarcinoma, NSCLC, HR+/HER2− breast cancer post‑CDK4/6 inhibitor, or platinum‑resistant high‑grade serous ovarian/related cancers receive the oral CDK7 inhibitor GTAEXS617 (transcription/cell‑cycle regulator) as monotherapy or combined with standard-of-care regimens. Eligible patients have ECOG 0–1 and adequate organ function; study explores safety, PK, and preliminary activity with tumor biopsies required.

ClinicalTrials.gov ID: NCT05985655

Single-Arm, Prospective, Multicenter Study Evaluating Safety, Tolerability, and Metabolism of Niraparib as Maintenance Following Front-Line Treatment for Ovarian Cancer in Women of African Ancestry

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm maintenance study of oral niraparib (PARP inhibitor) in women ≥18 who self-identify as Black/African ancestry (including Afro-Latinas) with newly diagnosed FIGO III–IV high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer who achieved CR/PR to first-line platinum therapy. Enrolls patients with adequate organ function and no platinum-refractory disease to assess safety, tolerability, pharmacokinetics, and disease control during up to 24 cycles of niraparib.

ClinicalTrials.gov ID: NCT06412120

Autophagy Maintenance (AUTOMAIN) Therapy in High-Grade Serous Ovarian Cancer: A Phase II Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with first platinum-sensitive recurrent high-grade serous (or predominantly serous) ovarian, fallopian tube, or primary peritoneal cancer who have achieved PR/CR after platinum-based chemotherapy plus bevacizumab and are continuing maintenance bevacizumab (typically enrolled 3–8 weeks after last chemo; ECOG 0–2; known BRCA/HRD status; generally not PARP maintenance candidates). Treatment adds oral hydroxychloroquine (late-stage autophagy inhibitor via lysosomal impairment) plus oral nelfinavir (HIV protease inhibitor that induces ER stress/UPR and may perturb autophagy) to standard bevacizumab 15 mg/kg IV q3w as maintenance.

ClinicalTrials.gov ID: NCT06971744

Phase II Non-Randomized, Unblinded, Single-Center Trial of Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer Versus Historical Best Supportive Care

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant or platinum-refractory high-grade serous ovarian carcinoma (ECOG 0–2) receive oral telmisartan, an angiotensin II type 1 receptor (AT1R) blocker, added to investigator-selected standard cytotoxic chemotherapy (preferred pegylated liposomal doxorubicin; or paclitaxel/nab-paclitaxel/docetaxel), with outcomes compared against historical best supportive care. The study assesses whether this combination improves progression-free survival and evaluates ctDNA dynamics and tolerability.

ClinicalTrials.gov ID: NCT06815497